InvestorsHub Logo
Followers 2
Posts 236
Boards Moderated 0
Alias Born 10/17/2015

Re: sirbutterknife post# 2883

Monday, 01/09/2017 11:03:13 AM

Monday, January 09, 2017 11:03:13 AM

Post# of 5001
Who cares....

It will be more beneficial for VRX to increase Salix sales team and benefit from a growing GI market, then sell at the price offered.

By the way, VRX is growing it's drug line:

BRIEF-Eyegate receives additional milestone payment from Valeant Pharmaceuticals for EGP-437

Jan 9 (Reuters) - Eyegate Pharmaceuticals Inc

* Eyegate receives additional milestone payment from Valeant Pharmaceuticals for EGP-437

* Remain on track to submit NDA for potential FDA approval of EGP-437 in Uveitis by end of year

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent BHC News